1. Home
  2. DSGN vs FUNC Comparison

DSGN vs FUNC Comparison

Compare DSGN & FUNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DSGN
  • FUNC
  • Stock Information
  • Founded
  • DSGN 2017
  • FUNC 1900
  • Country
  • DSGN United States
  • FUNC United States
  • Employees
  • DSGN N/A
  • FUNC N/A
  • Industry
  • DSGN Biotechnology: Pharmaceutical Preparations
  • FUNC Major Banks
  • Sector
  • DSGN Health Care
  • FUNC Finance
  • Exchange
  • DSGN Nasdaq
  • FUNC Nasdaq
  • Market Cap
  • DSGN 224.8M
  • FUNC 202.8M
  • IPO Year
  • DSGN 2021
  • FUNC N/A
  • Fundamental
  • Price
  • DSGN $3.71
  • FUNC $28.37
  • Analyst Decision
  • DSGN Hold
  • FUNC
  • Analyst Count
  • DSGN 1
  • FUNC 0
  • Target Price
  • DSGN $4.00
  • FUNC N/A
  • AVG Volume (30 Days)
  • DSGN 93.8K
  • FUNC 17.5K
  • Earning Date
  • DSGN 08-04-2025
  • FUNC 07-21-2025
  • Dividend Yield
  • DSGN N/A
  • FUNC 3.10%
  • EPS Growth
  • DSGN N/A
  • FUNC 61.82
  • EPS
  • DSGN N/A
  • FUNC 3.49
  • Revenue
  • DSGN N/A
  • FUNC $79,403,000.00
  • Revenue This Year
  • DSGN N/A
  • FUNC $14.15
  • Revenue Next Year
  • DSGN N/A
  • FUNC $7.07
  • P/E Ratio
  • DSGN N/A
  • FUNC $8.14
  • Revenue Growth
  • DSGN N/A
  • FUNC 14.92
  • 52 Week Low
  • DSGN $2.60
  • FUNC $19.17
  • 52 Week High
  • DSGN $7.77
  • FUNC $42.50
  • Technical
  • Relative Strength Index (RSI)
  • DSGN 47.78
  • FUNC 35.78
  • Support Level
  • DSGN $3.66
  • FUNC $28.05
  • Resistance Level
  • DSGN $3.84
  • FUNC $30.72
  • Average True Range (ATR)
  • DSGN 0.25
  • FUNC 1.14
  • MACD
  • DSGN -0.02
  • FUNC -0.15
  • Stochastic Oscillator
  • DSGN 18.06
  • FUNC 8.63

About DSGN Design Therapeutics Inc.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

About FUNC First United Corporation

First United Corp is active in the financial services domain. The scope of its offering includes checking, savings, money market deposit accounts and certificates of deposit, business loans, personal loans, mortgage loans and lines of credit extended to both individuals and businesses. The bank also provides residential real estate construction loans to builders and individuals for single-family dwellings. The company's reportable operating segments include community banking and wealth management. The company generates the majority of its revenue from the Community Banking segment, which is engaged in delivering financial products and services, including various loan and deposit products, to consumer, business, and not-for-profit customers.

Share on Social Networks: